Table 1.
Clinical Characteristics of Study Population
| Trait | Group 1 (basal-bolus insulin), n = 5 | Group 2 (pump+blinded CGM), n = 6 | Group 3 (pump+nonblinded CGM), n = 5 | Pa |
|---|---|---|---|---|
| Gender, female, % | 60 | 50 | 60 | 0.94 |
| Age, years | 57.4 ± 15.0 | 47.3 ± 6.2 | 61.6 ± 9.0 | 0.10 |
| Race | 100% AA | 66.7% AA | 100% AA | 0.17 |
| 33.3% C | ||||
| T2DM duration, years | 18.2 ± 11.4 | 18.1 ± 8.4 | 18.4 ± 15.8 | 1.00 |
| T2DM medication, n (%) | ||||
| Insulin alone | 4 (80) | 2 (33) | 5 (100) | 1.00 |
| Oral agents+insulin | 1 (20) | 4 (67) | 0.30 | |
| Baseline HbA1c, % | 7.0 ± 0.6 | 7.9 ± 1.4 | 8.2 ± 2.7 | 0.53 |
| Baseline creatinine, mg/dL | 1.52 ± 1.06 | 3.33 ± 1.93 | 2.83 ± 1.28 | 0.25 |
| DM history, n (%) | ||||
| Neuropathy | 2 (40) | 3 (60) | 3 (60) | 1.00 |
| Retinopathy | 2 (40) | 1 (17) | 2 (40) | 0.66 |
| Nephropathy/CKD | 2 (40) | 2 (33) | 3 (60) | 0.83 |
| Hypertension | 4 (80) | 6 (100) | 5 (100) | 0.63 |
| Hyperlipidemia | 3 (60) | 5 (83) | 4 (80) | 0.66 |
| Admission diagnosis, n (%) | ||||
| Cardiovascular/Pulmonary | 4 (80) | 3 (50) | 1 (20) | 0.22 |
| Renal | 2 (33) | 2 (40) | 0.73 | |
| Dermatology | 1 (20) | 0.63 | ||
| Ophthalmology | 1 (17) | 1.00 | ||
| Hematology | 2 (40) | 0.17 | ||
| Endocrine | 1 (20) | 0.63 | ||
a
Compares all three groups.
AA, African American; C, Caucasian; CGM, continuous glucose monitoring; T2DM, type 2 diabetes mellitus.